DDInter1910 DDInter1055
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Valdecoxib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dextromethorphan
Dextromethorphan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxaparin
Enoxaparin {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Repaglinide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dextromethorphan
Dextromethorphan {u} (Compound) upregulates {v} (Gene) FKBP14
FKBP14 {u} (Gene) is upregulated by {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Repaglinide {u} may lead to a major life threatening interaction when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dextromethorphan
Dextromethorphan {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Repaglinide {u} may lead to a major life threatening interaction when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pegaspargase
Pegaspargase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Valdecoxib may cause a minor interaction that can limit clinical effects when taken with Dextromethorphan and Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levofloxacin (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Enoxaparin (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Levofloxacin (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levofloxacin (Compound)
Valdecoxib may cause a minor interaction that can limit clinical effects when taken with Dextromethorphan and Dextromethorphan (Compound) upregulates FKBP14 (Gene) and FKBP14 (Gene) is upregulated by Levofloxacin (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may lead to a major life threatening interaction when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Valdecoxib may cause a minor interaction that can limit clinical effects when taken with Dextromethorphan and Dextromethorphan (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Levofloxacin (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levofloxacin (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)